Endo Other Current Liabilities 2024-2025 | NDOI

Endo other current liabilities from 2024 to 2025. Other current liabilities can be defined as field containing the sum of all current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.

Endo Other Current Liabilities 2024-2025 | NDOI

Endo other current liabilities from 2024 to 2025. Other current liabilities can be defined as field containing the sum of all current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.5B
Zoetis (ZTS)$69.3B
Takeda Pharmaceutical (TAK)$47.9B
Daiichi Sankyo, - (DSNKY)$42.7B
BeOne Medicines - (ONC)$27.6B
Sandoz Group AG (SDZNY)$24.9B
Summit Therapeutics (SMMT)$18.9B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.4B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.3B
Stevanato Group S.p.A (STVN)$7.8B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.1B
Ionis Pharmaceuticals (IONS)$6.8B
Grifols, S.A (GRFS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.3B
Soleno Therapeutics (SLNO)$4.2B
Crinetics Pharmaceuticals (CRNX)$3.1B
Hypermarcas (HYPMY)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
BioCryst Pharmaceuticals (BCRX)$1.9B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B